Navigation Links
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Date:9/24/2008

Separate survey shows high prevalence of "bothersome" vaginal atrophy symptoms among sexually active and non-sexually active postmenopausal women; results presented today at 19th Annual North American Menopause

Society Meeting

ANN ARBOR, Mich., Sept. 24 /PRNewswire/ -- Additional results of a Phase 3 study for Ophena(TM) (ospemifene tablets) for the treatment of symptoms of vulvovaginal atrophy (VVA) in postmenopausal women showed that Ophena(TM) significantly improves a broad range of clinical signs of vulvovaginal atrophy, including petechiae, pallor, friability, vaginal dryness and redness in mucosa. These are all visual observations of VVA assessed during gynecological examination and were pre-defined secondary endpoints in the study. Results were announced today by QuatRx Pharmaceuticals in a poster presentation at the 19th Annual North American Menopause Society meeting in Orlando, Florida.

Vulvovaginal atrophy is a common and progressive condition associated with menopause. Earlier this year, QuatRx announced a Phase 3 study for Ophena(TM) met all four of its co-primary endpoints. The results of the study showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), two of the most bothersome symptoms associated with VVA. The study also demonstrated favorable effects of Ophena(TM) on vaginal wall health as compared to placebo, measured as changes in the proportion of parabasal and superficial cells in the vaginal epithelium, as well as a favorable effect on vaginal pH levels.

The multi-center, double-blind, placebo-controlled study was conducted at 80 U.S. centers and involved 826 postmenopausal women. The additional results announced today showed that after 12 weeks of treatment, the mean scores for common clinical signs of vaginal atrophy were decreased by a statistically significant margin in the Ophena(TM) groups when compared with placebo. These positive effects of Ophena(TM) were already evident at week 4, as the mean scores of all signs were significantly decreased by Ophena(TM) when compared to placebo. Ophena(TM) was generally well tolerated and demonstrated a favorable safety profile in this study.

"Vulvovaginal atrophy represents a serious health issue that can have a profound negative impact on the quality of life for millions of postmenopausal women," said David Portman, M.D., director of the Columbus Center for Women's Health Research in Ohio. "These results show that Ophena(TM) has the potential to significantly improve multiple clinical signs of vaginal atrophy in symptomatic patients. These are significant results for a non-estrogen oral therapy and may pave the way for an alternative approach to a very common and concerning condition for postmenopausal women."

Also presented at the meeting were results from a study conducted by QuatRx which surveyed the prevalence and impact of vaginal atrophy symptoms and perceptions about the safety of treatment with estrogen. In a survey of 1038 postmenopausal women across the United States, Dr. Nanette Santoro, Albert Einstein College of Medicine, a key member of the research team, found that there was a high prevalence of vaginal atrophy symptoms among these women (overall 45%). The findings were consistent for both sexually active and non-sexually active respondents. A majority of women in the survey considered the symptoms of vaginal atrophy to be "bothersome." The study also showed a majority of women had either discontinued or never used hormone therapy due to concerns about health risks associated with estrogen and based on physician advice. The prevalence of vaginal atrophy symptoms was highest among women who either never used or discontinued estrogen treatment. Among women in the study who remained on estrogen therapy, a majority expressed concerns about long-term safety and 70% had been on treatment for five years or longer.

"These results shed new light on the prevalence and impact of vaginal atrophy among both sexually active and non-sexually active postmenopausal women, and confirm that there is a high degree of both awareness and concern about the health risks associated with estrogen therapy among these women," said Chris Nicholas, chief operating officer at QuatRx. "These data provide further support for the need for alternatives to estrogen for the treatment of vulvovaginal atrophy in the years ahead."

Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a non-estrogen alternative for the treatment of vulvovaginal atrophy. The only FDA approved products currently available to treat VVA contain the hormone estrogen. Treatment with hormone therapy has been associated with certain health risks including an increased risk of breast cancer.

"These data are yet another confirmation that Ophena(TM) has the potential to be the first non-estrogen treatment option that provides a clear clinical benefit for postmenopausal women with vulvovaginal atrophy," said Robert Zerbe, M.D., president and chief executive officer of QuatRx. "We are working hard in our development efforts to provide women another choice for this highly prevalent and progressive condition."

About Vulvovaginal Atrophy

Vulvovaginal atrophy is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain and bleeding during sexual intercourse. The decline in estrogen also contributes to an increase in vaginal pH, creating an environment more susceptible to infection. It is estimated that up to 45-75% of post-menopausal women have chronic symptoms of VVA. Current prescription treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. SERMs that are currently approved and marketed in the United States have not been shown to have beneficial effects on vaginal tissue and none are approved for use in treating symptoms of VVA.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and an advanced preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (becocalcidiol), a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta-HSD enzymes. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases and other Company information, please visit http://www.quatrx.com.


'/>"/>
SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
2. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
9. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
10. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
11. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ... tests and pathology services for evaluating risks of cancer, ... January 13, 2017 from the NASDAQ Listing Qualifications notifying ... requirement of the NASDAQ Stock Market to maintain a ... The letter noted that for the last 10 ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has announced ... report to their offering. ... This unique and comprehensive report, identifies and profiles the leading 200 ... across the globe from the United States and ... China . Profile information for each ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... Review, 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European ... from touchNEUROLOGY, Catherine Amey reports that ...
Breaking Medicine Technology:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a point of difference. Eden Activewear is a stand-out company for several differences ... exclusively online and only manufacture on demand, this is called 'Agile' manufacturing - ...
(Date:1/17/2017)... ... 2017 , ... Healthful Balance announces the national release of ... by Ed Stroup, was created to offer the highest quality vitamins and supplements ... service. Healthful Balance products can be purchased online through their website, or can ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s ... of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, ... group of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New ... eye care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment ... Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of ...
Breaking Medicine News(10 mins):